The efficacy of chondroitin sulfate-4,6 in treatment of patients with osteoarthritis and hyperuricemia

Эффективность хондроитин-сульфата-4,6 у пациентов с остеоартрозом и сопутствующей гиперурикемией.
Anna Krylova 1
More Detail
1 National Medical Academy of Postgraduate Education named after PL Shupyk, Department of Therapy and Rheumatology, Kiev, Ukraine
J CLIN MED KAZ, Volume 4, Issue 38, pp. 60-64.
Download Full Text (PDF)


Aim of the study. To investigate the efficacy of chondroitin sulfate in treatment of osteoarthritis and hyperuricemia and its effects on the dynamics ofthe inflammatory process, purine, carbohydrate and lipid metabolism markers.
Materials and methods. In this study was included 32 patients with hyperuricemia and osteoarthritis (26 women and 6 men), aged 35-75 years. Estimated dynamics of VAS, indices Lequesne, WOMAC, uric acid, IL-1β, IGF-1, NO, general clinical indicators. Statistical analysis was performed using SPSS Statistics.
Results. The study found a significant reduction in pain by VAS, indices WOMAC, Lequesne after 6 months of treatment. Any dynamics of laboratory tests – levels of serum glucose, markers of lipid metabolism, markers of liver function,serum creatininewere not observed. After 6 months of treatment, we obtained significant decreasedlevels of IL-1, NO, CRP and significant increasedlevel ofIGF-1. Increased uric acid levels were found.
Conclusion. The use ofchondroitin sulfate avian origin (chondroitin-4-sulfate, 72%) in the treatment of patients with osteoarthritis has pathogenetic base and clinical perspective, but it should be taken into account its effect on uric acid levels and in the futureshould be planed a differentiated approach to the treatment of patients with osteoarthritis and hyperuricemia.


Krylova A. The efficacy of chondroitin sulfate-4,6 in treatment of patients with osteoarthritis and hyperuricemia. Journal of Clinical Medicine of Kazakhstan. 2015;4(38):60-4.


  • Bijlsma J.W., Berenbaum F., Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice, Lancet, 2011, Vol.377, pp. 2115–2126.
  • Bruyere O.,Cooper C.,Pelletier J.P., et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Seminars in Arthritis and Rheumatism, 2014, Vol. 44 (3), pp. 253–263.
  • Yves Henrotin. Review: Advances in the treatment of osteoarthritis and the role of chondroitin sulphate, European Musculoskeletal Review, 2010, Vol.5(2), pp.11-17.
  • van Dijk G.M., Veenhof C, Schellevis F. et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee, BMC Musculoskelet Disord, 2008, No. 26 (9), p.95.
  • Egea J., Garsia A.G., VergesJ., et al. Antioxidant, anti-inflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans, Osteoarthritis and Cartilage, 2010, Vol. 18(1), pp. 24-27. 
  • Herrero-Beaumont G., Marcus M.E., Sanchez-Pernaute O., et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis, British Journal of Pharmacology, 2008, Vol. 154, pp.843-851.
  • Altman R., Asch E., Bloch D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee, Arthritis Rheum, 1986, Vol. 29 (8), pp.1039–1049.
  • Hamburger M., Baraf H.S., Adamson T.C., et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia, Phys. Sportsmed, 2011, No.39(4), pp.98–123.
  • Kellgren J.H., Lawrence J.S Radiological assessment of osteoarthrosis, Annals of The Rheumatic Diseases, 1957, Vol. 16, pp. 494-50.
  • Mediko-biologicheskaja statistika, Glanc. S. Per. s angl, M.: Praktika, 1998, 459 p.
  • Schneider H., Maheu E., Cucherat M. Symptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A MetaAnalysis of Randomized Placebo-Controlled Trials Performed with Structum /Heinz Schneider, Emmanuel Maheu, Michel Cucherat, Open Rheumatol J., 2012, No.6, pp.183–189.
  • Volpi N. Curr J.Chondroitin sulphate for the treatment of osteoarthritis, Anti-Inflammatory and Anti-Allergy Agents, 2005, Vol.4, pp. 221-234.
  • J. Martel-Pelletier, D. Lajeuness, J.P. Pelletier. Etiopathogenesis of osteoarthrtitis, A textbook of Rheumatology, 2005, pp. 2199–2226.
  • Bassleer C.T., Combal JP, Bougaret S. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters, Osteoarthritis Cartilage, 1998,Vol.6, pp.196–204.
  • Chan P.S. Caron J.P., Orth M.W. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants, Am J VetRes, 2005, Vol.66, pp.1870–1876.
  • Volpi N. Influence of chondroitin sulfate charge density, sulfate group position, and molecular mass on Cu2+-mediated oxidation of human low-density lipoproteins: effect of normal human plasma-derived chondroitin sulfate. J. Biochem, 1999,Vol.125, pp.297–304.
  • Campo G.M., Avenoso A., Campo S. Reduction of DNA fragmentation and hydroxyl radical production by hyaluronic acid and chondroitin-4-sulphate in iron plus ascorbate-induced oxidative stress in fibroblast cultures. Free Radic. Res, 2004, Vol.38, pp. 601–611.
  • Campo G.M. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res. Ther, 2003, Vol.5, pp.122–131.
  • Hutchison M.R., Bassett M.H., White P.C. Insulin like growth factor I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation, Endocrinology, 2007, Vol. 148(7), pp.3122-3130.
  • Burt H.M., Dutt Y.C. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates, Ann Rheum Dis, 1986,Vol. 45, pp. 858–864.